NASDAQ$NKTR
Nektar Therapeutics · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2021.
Nektar Therapeutics reported a decrease in revenue for Q1 2021, with $23.6 million compared to $50.6 million in Q1 2020. The net loss for the quarter was $123.0 million, or $0.68 per share, compared to a net loss of $138.7 million, or $0.78 per share, in the same quarter of the previous year. Cash and investments in marketable securities were approximately $1.1 billion as of March 31, 2021.
- Revenue was $23.6 million, down from $50.6 million in Q1 2020, due to the recognition of a milestone payment from Bristol-Myers Squibb in the previous year.
- Total operating costs and expenses decreased to $133.0 million from $184.2 million in Q1 2020, primarily due to impairment charges in the previous year and a decrease in R&D expense.
- Research and development expenses decreased to $95.6 million from $109.0 million in Q1 2020, mainly due to lower manufacturing costs for bempegaldesleukin.
- Net loss was $123.0 million, or $0.68 per share, compared to a net loss of $138.7 million, or $0.78 per share, in Q1 2020.
Headline financials
Revenue & EPS history
Nektar · Revenue · Quarterly
$23.6M
Forward guidance
Nektar is progressing with its clinical pipeline, including registrational studies for bempegaldesleukin and Phase 1 studies for NKTR-255. Eli Lilly is conducting Phase 2 studies for NKTR-358.
Tailwinds
- Momentum is building with the clinical pipeline of novel cytokine therapeutics.
- A robust development program for bempegaldesleukin is focused on pursuing large front-line and adjuvant tumor settings.
- Five registrational studies are underway in melanoma, renal cell carcinoma, and bladder cancer.
- A sixth registrational study for bempegaldesleukin plus pembrolizumab in head and neck cancer is expected to be initiated later this year.
- The first data for the PROPEL study evaluating bempegaldesleukin plus pembrolizumab in patients with metastatic non-small cell lung cancer is expected in the second half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.7%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.8%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+24.8%
Q3 2017
Best reaction
-27.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -7.9% | -32.6% | |
| Q4 2025 | +4.0% | +4.0% | +10.1% | |
| Q3 2025 | +1.9% | +4.6% | +3.2% | |
| Q1 2025 | -4.1% | +16.1% | +8.1% | |
| Q4 2024 | -0.6% | +7.3% | -24.4% | |
| Q3 2024 | +0.7% | -5.8% | -26.6% | |
| Q2 2024 | -5.9% | -2.5% | -5.1% | |
| Q1 2024 | +7.3% | +7.9% | -23.2% | |
| Q4 2023 | +13.3% | +16.7% | +33.3% | |
| Q3 2023 | -5.6% | -15.1% | -3.8% | |
| Q2 2023 | -10.8% | -8.8% | -42.2% | |
| Q1 2023 | -2.6% | -5.2% | -22.1% | |
| Q4 2022 | +8.6% | +12.9% | -54.0% | |
| Q3 2022 | +3.6% | +4.1% | -16.2% | |
| Q2 2022 | +9.2% | +5.4% | -10.3% | |
| Q1 2022 | -6.7% | -17.0% | -22.1% | |
| Q4 2021 | +10.0% | +5.2% | -44.2% | |
| Q3 2021 | -21.0% | -18.8% | -36.4% | |
| Q2 2021 | +1.0% | -4.0% | +1.6% | |
| Q1 2021 | +7.6% | +3.3% | -8.3% | |
| Q4 2020 | -0.4% | +4.3% | -12.2% | |
| Q3 2020 | +2.7% | -0.8% | +2.5% | |
| Q2 2020 | +0.5% | -6.2% | -13.0% | |
| Q1 2020 | +6.3% | +11.3% | +14.0% | |
| Q4 2019 | -2.8% | -9.2% | -19.5% | |
| Q3 2019 | +0.9% | +13.2% | +10.3% | |
| Q2 2019 | -27.4% | -34.5% | -40.9% | |
| Q1 2019 | +10.5% | +1.7% | +2.9% | |
| Q4 2018 | -7.1% | -6.4% | -18.1% | |
| Q3 2018 | -2.1% | +2.5% | +2.5% | |
| Q2 2018 | +8.7% | +8.6% | +19.0% | |
| Q1 2018 | +2.1% | +7.2% | -30.4% | |
| Q4 2017 | +18.8% | +13.3% | +22.8% | |
| Q3 2017 | +24.8% | +33.9% | +125.8% | |
| Q2 2017 | -7.8% | -9.8% | +11.0% | |
| Q1 2017 | +5.8% | +9.9% | +4.1% | |
| Q4 2016 | +13.1% | +9.9% | +79.4% | |
| Q3 2016 | -1.1% | +5.1% | -0.6% | |
| Q2 2016 | +1.6% | +0.5% | +7.4% | |
| Q1 2016 | -12.3% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | -5.6% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | -1.8% | — | — | |
| Q2 2014 | +7.4% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +15.8% | — | — | |
| Q2 2013 | +11.9% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | +1.6% | — | — | |
| Q3 2012 | -14.1% | — | — | |
| Q2 2012 | +0.6% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +9.5% | — | — | |
| Q3 2011 | -1.5% | — | — | |
| Q2 2011 | -5.4% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q4 2010 | -4.9% | — | — | |
| Q3 2010 | -4.8% | — | — | |
| Q2 2010 | -2.2% | — | — | |
| Q1 2010 | -10.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro